Survival analysis according to CEBPA mutation status (CEBPA^wt, CEBPA^bZIP-inf, and CEBPA^others) within the cohort of 4461 patients receiving intensive treatment. Kaplan-Meier plots showing OS (A) and EFS (B). (C) Frequency distribution of additional gene mutations identified in patients with CEBPA^bZIP-inf and CEBPA^others mutant genes (frequency of at least 5% in one subgroup). RAS signaling, including KRAS, NRAS, PTPN11, CBLB; spliceosome, including SF3B1, SRSF2, and ZRSR2; and methylation, including DNMT3A, IDH1, IDH2, and TET2. Numbers of patients at risk and results of log-rank tests from pairwise comparisons are provided below the x-axis.